Ligand Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Net Income	-3.3	-3.16	-0.75
Depreciation & Amortization	0.09	0.12	-
Loss (Gain) From Sale of Assets	-0.67	-3.14	-
Loss (Gain) From Sale of Investments	0.88	0.99	-
Stock-Based Compensation	0.31	0.11	-
Other Operating Activities	-0.43	4.17	0.01
Change in Accounts Payable	-0.49	0.27	0.47
Change in Other Net Operating Assets	-0.6	-0.08	-0.07
Operating Cash Flow	-4.2	-0.71	-0.34
Capital Expenditures	-0.78	-0.12	-0.47
Cash Acquisitions	-	0.11	-
Investment in Securities	-1.5	-0.03	-
Investing Cash Flow	-2.28	-0.04	-0.47
Long-Term Debt Issued	0.3	0.1	-
Total Debt Issued	0.3	0.1	2.03
Long-Term Debt Repaid	-0.12	-0.04	-
Net Debt Issued (Repaid)	0.18	0.07	2.03
Issuance of Common Stock	5.26	1.61	0.18
Other Financing Activities	-0.18	-	-
Financing Cash Flow	5.26	1.67	2.21
Miscellaneous Cash Flow Adjustments	-	-	-1.39
Net Cash Flow	-1.21	0.92	-
Free Cash Flow	-4.98	-0.83	-0.82
Free Cash Flow Per Share	-0.12	-0.06	-0.07
Cash Interest Paid	0.02	-	-
Cash Income Tax Paid	0.03	-	-
Levered Free Cash Flow	-2.24	1.06	-
Unlevered Free Cash Flow	-2.18	1.14	-

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.